Renowned Brain Tumor Experts to Present at 2012 ABTA Patient and Family Conference
More than 30 national
brain tumor experts will present on a variety of topics at the 2012 ABTA
Patient and Family Conference, taking place July 27-29 at the Marriott Renaissance
Chicago O’Hare Suites Hotel. The Conference provides a unique opportunity for
brain tumor patients and their families to not only hear from, but also ask
questions of these top experts in the field. Featured presenters include:
- Terri Armstrong, PhD, ANP-BC, FAANP – University of Texas Health Science Center at Houston
- Amar Gajjar, MD – St. Jude Children’s Research Hospital
- Steven Keir, DrPH, MPH – The Preston Robert Tisch Brain Center at Duke University
- M. Kelly Nicholas, MD, PhD – University of Chicago Medicine
- Joon Um, MD – Mayo Clinic
- Susan Chang, MD – University of California, San Francisco
Space is limited, so register today at www.braintumorconference.org.
Proton Therapy Webinar to Be Presented in June
“Understanding Proton Therapy,” the first in a series of free American Brain Tumor Association webinars, will be offered on Friday, June 22, at 1:00 pm, CDT. The webinar will be presented by Anita Mahajan, MD, medical director of the MD Anderson Proton Therapy Center. Webinar participants will also be able to take part in an online Q&A session with Dr. Mahajan. To register online, go to bit.ly/protontherapywebinar.
Supportive Care Needs in Patients with Primary Malignant Brain Tumors and Caregivers
A recent study, which reviewed 60 articles on the psychosocial and supportive needs of primary malignant brain tumor patients and caregivers, found that patients with brain tumors expressed a need for specific information on prognosis; a need for diagnostic, prognostic and treatment information in differing formats; and information about alternatives to the proposed treatment, in addition to other informational concerns. The literature was reviewed on the basis of communication and information needs; psychological health and supportive care services; cognitive symptoms and rehabilitation; palliative and end of life care; and the experience of caregivers. The study results, presented in the April 2012 issue of Neuro-Oncology, highlight the need for establishing the best methods of providing care, information and interventions. Click here to read the abstract online.
Protein Linked to Angiogenesis in Glioblastoma
ABTA Basic Research Fellowship Alumni, Beata Pyrzynska, PhD, is among a group of researchers investigating the potential link between the protein, P14ARF, and the growth of the blood supply to glioblastoma tumors. The article, "P14ARF Inhibits Human Glioblastoma-Induced Angiogenesis by Upregulating the Expression of TIMP3", published in the April 2012, Journal of Clinical Investigation, reports tumor suppressive activity using cofactor P14ARF to reducing malignant glioma tumor angiogenesis. To read the full article, click here.
Hearing Loss in Patients Treated for Medulloblastoma
A recent retrospective study of 33 patients with medulloblastoma who received radiation and cisplatin chemotherapy treatment concluded that an association between hearing loss (ototoxicity) and cerebrospinal fluid shunting may exist. Although ototoxicity from chemotherapy and radiation therapy can occur, the researchers suggest that changes in CSF pressure due to shunting may impact the cochlear physiology, resulting in hearing loss. The study, published in the April 2012 Journal of Neurosurgery: Pediatrics, used a baseline audiological test with 3 follow-up tests. Ototoxicity occurred in 70% in the group without shunts, whereas all of the shunted patients in this study developed ototoxicity. Read more here.
Differentiating GBM from Glioblastoma with Oligodendroglioma
Researchers in China recently investigated 219 primary glioblastomas (GBM) for the presence of oligodendroglioma (GBMO). The authors suggest that the clinical behavior and genetic alterations of GBMO differ from primary GBM, but resemble that of secondary GBMs. The presence of GBMO appears to be a favorable prognostic and predictive factor. The findings, presented in the April 2012
Neuro-Oncology, suggest a benefit to classifying and stratifying these tumors by the presence of an oligodendroglioma component. For additional study information, click here.
Take the Shirt off Our Backs! (Well, sort of...)
Do you like our exclusive ABTA Chicago skyline t-shirt? You can
be the proud owner of one, by registering and fundraising or self donating $35
for the Saturday, May 12 Chicago Breakthrough for Brain Tumors 5K Run/Walk.
With only one month until the event, now is the time to register and
raise funds to support the programs of the American Brain Tumor Association.
Register at www.breakthroughforbraintumors.org.
Join Us As We "Breakthrough for Brain Tumors" in NYC
Registration is now open for the inaugural New York City Breakthrough for Brain Tumors 5K. This all-ages event will take place on Saturday, November 10 at Hudson River Park in New York City, and will feature a chip-timed, certified 5K (3.1 mile) run followed by an untimed walk. Visit www.breakthroughforbraintumors.org to register.
Move Further. Move Forward. Run with Team Breakthrough.
It's been sold out for weeks, but we still have a very limited number of bibs for the Sunday, October 7 Bank of America Chicago Marathon - if you sign up to run with Team Breakthrough. And we're not just offering you a spot in the big race: We've partnered with Fleet Feet Sports and Chicago Endurance Sports to provide you with a custom 20-week pre-event training program. If you’re interested in participating, call our Events Department at 800-886-1281 or visit www.abtateambreakthrough.org.
Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely to brain tumor research. For nearly 40 years, the Chicago-based ABTA has been providing critical funding to researchers working toward breakthroughs in brain tumor diagnosis, treatment and care, and is the only national organization providing comprehensive resources that support the complex needs of brain tumor patients and caregivers.
Make a donation to the American Brain Tumor Association.
This information is provided by the American Brain Tumor Association, 8550 W. Bryn Mawr Ave., Suite 550, Chicago, IL 60631. For more information about the American Brain Tumor Association, call toll-free (866) 659-1030, write ABTAcares@abta.org or visit www.abta.org
"American Brain Tumor Association" and "TrialConnect" are registered trademarks of the American Brain Tumor Association. The ABTA logo, the "Breakthrough for Brain Tumors" name and logo, and the "Team Breakthrough" name and logo are trademarks of the American Brain Tumor Association. All rights reserved.
Update Email Preferences | Forward to a Friend | Unsubscribe
©2012 American Brain Tumor Association
Having Fun Raising Funds
April 14, 2012
April 21, 2012
April 22, 2012
Tuttles Hopkins, MN
April 28, 2012
May 4, 2012
Park Ridge, IL
May 12, 2012
May 12, 2012
June 2, 2012
June 9, 2012
June 9, 2012
UConn Storrs Campus
July 7, 2012
July 20, 2012
Columbia Station, OH
July 29, 2012
San Francisco, CA
September 22, 2012
hosting an ABTA event? Contact us at email@example.com.
Discover Community Support with ABTA Connections
ABTA's Connections Online Support Community links patients, families, friends, caregivers and health care professionals with each other for support and inspiration. The online community was created to provide a safe place to visit, join and interact with over 500 members of the brain tumor community nationally and around the world.
Find a Clinical Trial Through TrialConnect
The American Brain Tumor Association offers a service that links brain tumor patients with appropriate clinical trials based on tumor type and treatment history. TrialConnect, a free and confidential service administered by EmergingMed, is offered in English and Spanish. Read more.
Our Care Consultants provide brain tumor information, support and education for patients, families and health care professionals. Write
or call our toll-free CareLine at (800) 886-ABTA (2282).